Castration-resistant prostate cancer: AUA guideline

Journal of Urology

Volumn 190, Issue 2, 2013, Pages 429-438

  Cookson, Michael S ^a   Roth, Bruce J ^a   Dahm, Philipp ^a   Engstrom, Christine ^a   Freedland, Stephen J ^a   Hussain, Maha ^a   Lin, Daniel W ^a   Lowrance, William T ^a   Murad, Mohammad Hassan ^a   Oh, William K ^a   Penson, David F ^a   Kibel, Adam S ^a  

^a American Urological Association   (United States)

Author keywords

androgen antagonists; drug therapy; immunotherapy; prostatic neoplasms

Indexed keywords

ABIRATERONE; ANTIANDROGEN; BICALUTAMIDE; CABAZITAXEL; CALCIUM; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; FLUTAMIDE; KETOCONAZOLE; MITOXANTRONE; NILUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; SAMARIUM 153; SIPULEUCEL T; STEROID; STRONTIUM 89; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; BONE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL OBSERVATION; DIARRHEA; EDEMA; FATIGUE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; META ANALYSIS; OSTEOLYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; SEIZURE; SYSTEMATIC REVIEW;

ADT; ANDROGEN ANTAGONISTS; ANDROGEN DEPRIVATION THERAPY; CASTRATION-RESISTANT PROSTATE CANCER; CRPC; DRUG THERAPY; FDA; FOOD AND DRUG ADMINISTRATION; H&P; HISTORY AND PHYSICAL; IMMUNOTHERAPY; MCRPC; METASTATIC CASTRATION-RESISTANT PROSTATE CANCER; OS; OVERALL SURVIVAL; PFS; PROGRESSION-FREE SURVIVAL; PROSTATE SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PSA; QOL; QUALITY OF LIFE; SKELETAL-RELATED EVENT; SRE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 84880009495     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.005     Document Type: Article

References (42)

1. M. Faraday, H. Hubbard, B. Kosiak Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association BJU Int 104 2009 294
2. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10
3. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
4. D.P. Petrylak, C.M. Tangen, M.H.A. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513
5. Y. Fujii, S. Kawakami, H. Masuda Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy BJU Int 97 2006 1184
6. K. Fujikawa, Y. Matsui, S. Fukuzawa Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate cancer Eur Urol 37 2000 218
7. Kojima S, Suzuki H, Akakura K, et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171: 679.
8. H. Miyake, I. Hara, H. Eto Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer BJU Int 96 2005 791
9. M. Nakabayashi, M.M. Regan, D. Lifsey Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC) J Clin Oncol 23 2005 4683
10. K. Nishimura, N. Arichi, S. Tokugawa Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer Int J Urol 14 2007 264
11. K.A. Harris, V. Weinberg, R.A. Bok Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J Urol 168 2002 542
12. M. Nakabayashi, W. Xie, M.M. Regan Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen- independent prostate cancer Cancer 107 2006 975
13. L.S. Ngo, A. Yeo, A.S. Wong Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and the Cancer Institute, Singapore Ann Acad Med Singapore 36 2007 811
14. M. Scholtz, R. Jennrich, S. Strum Long-term outcome in men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone J Urol 173 2005 1947
15. E.J. Small, A. Baron, R. Bok Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma Cancer 80 1997 1755
16. M.E. Taplin, M.M. Regan, Y.J. Ko Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7099
17. S. Wilkinson, G. Chodak An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer Eur Urol 45 2004 581
18. C.J. Ryan, M.R. Smith, J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138
19. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
20. E.J. Small, S. Halabi, N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025
21. I.F. Tannock, D. Osoba, M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756
22. I.G. Finlay, M.D. Mason, M. Shelley Radioisotopes for the palliation of metastatic bone cancer: a systematic review Lancet Oncol 6 2005 392
23. N. Pandit-Taskar, M. Batraki, C.R. Divgi Radiopharmaceutical therapy for palliation of bone pain from osseous metastases J Nucl Med 45 2004 1358
24. P.W. Kantoff, S. Halabi, M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study J Clin Oncol 17 1999 2506
25. J.S. de Bono, C.J. Logothetis, A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995
26. J.S. de Bono, S. Oudard, M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial Lancet 376 2010 1147
27. H.I. Scher, K. Fizazi, F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Eng J Med 367 2012 1187
28. D. Keizman, P. Huang, M.A. Carducci Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression Prostate 72 2012 461
29. T.M. Beer, C.J. Ryan, P.M. Venner Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer Cancer 112 2008 326
30. M.R. Smith, W.C. Lee, J. Brandman Gonadotropin-releasing hormone agonists and fracture risk; a claims-based cohort study of men with non-metastatic prostate cancer J Clin Oncol 23 2005 7897
31. V.B. Shahinian, Y.F. Kuo, J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154
32. H.A. Bischoff-Ferrari, W.C. Willett, J.B. Wong Fracture prevention with vitamin D supplementation JAMA 293 2005 2257
33. M. Datta, G.G. Schwartz Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer: a critical review Oncologist 17 2012 1171
34. L. Lind, E. Skarfors, L. Berglund Serum Calcium: A new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years J Clin Epidemiol 50 1997 967
35. K. Li, R. Kaaks, J. Linseisen Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition Study (EPIC-Heidelberg) Heart 98 2012 920
36. G.G. Schwartz, H.G. Skinner A prospective study of total and ionized serum calcium and time to fatal prostate cancer Cancer Epidemiol Biomarkers Prev 21 2012 1768
37. H.G. Skinner, G.G. Schwartz Serum calcium and incident and fatal prostate cancer in the National Health and Nurtrition Examination Survey Cancer Epidemiol Biomarkers Prev 17 2008 2302
38. K. Fizazi, M. Carducci, M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study Lancet 377 2011 813
39. F. Saad, D.M. Gleason, R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879
40. A.N. Serafini, S.J. Houston, I. Resche Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled study J Clin Oncol 16 1998 1574
41. O. Sartor, R.H. Reid, P.J. Hoskin Samarium-153-lexidronam complex for the treatment of painful bone metastases in hormone refractory prostate cancer Urology 63 2004 940
42. O. Sartor, R.H. Reid, D.L. Bushnell Safety and efficacy of repeat administration of samarium sm-153 lexidronam to patients with metastatic bone pain Cancer 109 2007 637